雷珠单抗与阿柏西普治疗糖尿病黄斑水肿的疗效对比.

Objective To explore the efficacy of treating diabetic macular edema with aflibercept and ranibizumab. and to compare the effects of these two drugs on central macular thickness (CMT), best-corrected visual acuity (BCVA), and central macular volume (CMV). Methods From February 2021 to February 2023.100 patients with diabetic macular edema were admitted to the hospital and randomly divided into two groups using the envelope method: the observation group (50 patients, 50 eyes) treated with aflibercept, and the control group (50 patients, 50 eyes) treated with ranibizumab. The efficacy, CMT, BCVA,CMV, and com- plications of the two groups were compared. Results There was no statistically significant difference in the overall efficacy between the two groups (P>0.05). There was no significant difference in the pre-treatment values of CMT and CMV between the two groups (P>0.05). However, the CMT and CMV values at 4 and 8 months post-treatment were significantly lower in the observation group than in the control group (P< 0.05). There was no significant difference in BCVA values before treatment, and at 4 and 8 months after treatment between the two groups (P>0.05). The rates of complications such as cataract, vitreous hemorrhage. and conjunctivitis were similar between the two groups (P>0.05). Conclusion Both aflibercept and ranibizumab can be effective in treating diabetic macular edema. However, aflibercept has a more pronounced advantage in reducing CMT and decreasing CMV, with fewer complications. [ABSTRACT FROM AUTHOR]